OAS2 and neoplasm: The invasive front (arrow) showed stronger GSN immunoreactivity than the central tumor in seven patients (35%; 4 patients with recurrence and 3 patients without recurrence), whereas OAS2 immunoreactivity was not different between invasive front and central tumor regardless of recurrence (S4 Fig).